Show simple item record

dc.contributor.authorSiow, ZR
dc.contributor.authorDe Boer, RH
dc.contributor.authorLindeman, GJ
dc.contributor.authorMann, GB
dc.date.accessioned2020-12-18T04:22:22Z
dc.date.available2020-12-18T04:22:22Z
dc.date.issued2018-01-01
dc.identifierpii: ijwh-10-089
dc.identifier.citationSiow, Z. R., De Boer, R. H., Lindeman, G. J. & Mann, G. B. (2018). Spotlight on the utility of the Oncotype DX (R) breast cancer assay. INTERNATIONAL JOURNAL OF WOMENS HEALTH, 10, pp.89-100. https://doi.org/10.2147/IJWH.S124520.
dc.identifier.issn1179-1411
dc.identifier.urihttp://hdl.handle.net/11343/256166
dc.description.abstractThe Oncotype DX® assay was developed to address the need for optimizing the selection of adjuvant systemic therapy for patients with estrogen receptor (ER)-positive, lymph node-negative breast cancer. It has ushered in the era of genomic-based personalized cancer care for ER-positive primary breast cancer and is now widely utilized in various parts of the world. Together with several other genomic assays, Oncotype DX has been incorporated into clinical practice guidelines on biomarker use to guide treatment decisions. The Oncotype DX result is presented as the recurrence score which is a continuous score that predicts the risk of distant disease recurrence. The assay, which provides information on clinicopathological factors, has been validated for use in the prognostication and prediction of degree of adjuvant chemotherapy benefit in both lymph node-positive and lymph node-negative early breast cancers. Clinical studies have consistently shown that the Oncotype DX has a significant impact on decision making in adjuvant therapy recommendations and appears to be cost-effective in diverse health care settings. In this article, we provide an overview of the validation and clinical impact studies for the Oncotype DX assay. We also discuss its potential use in the neoadjuvant setting, as well as the more recent prospective validation trials, and the economic and utility implications of studies that use a lower cutoff score to define low-risk disease.
dc.languageEnglish
dc.publisherDOVE MEDICAL PRESS LTD
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0
dc.titleSpotlight on the utility of the Oncotype DX (R) breast cancer assay
dc.typeJournal Article
dc.identifier.doi10.2147/IJWH.S124520
melbourne.affiliation.departmentMedical Biology (W.E.H.I.)
melbourne.affiliation.departmentMedicine (RMH)
melbourne.affiliation.departmentSurgery (RMH)
melbourne.affiliation.facultyMedicine, Dentistry & Health Sciences
melbourne.source.titleInternational Journal of Women's Health
melbourne.source.volume10
melbourne.source.pages89-100
dc.rights.licenseCC BY-NC
melbourne.elementsid1312856
melbourne.contributor.authorLindeman, Geoffrey
melbourne.contributor.authorMann, Gregory
melbourne.contributor.authorSiow, Zhen
dc.identifier.eissn1179-1411
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record